All In Biotech

Free tool

FAERS Monitor: Exondys 51

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206488 or its brand name (Exondys 51, Eteplirsen). Reports on generic versions are filed under their own applications.

Reports

2,414

Serious

495

21% of reports

Hospitalization

356

Death reported

68

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue697
  • no adverse event550
  • intentional dose omission279
  • poor venous access187
  • device issue182
  • pyrexia110
  • covid-1987
  • malaise74
  • pneumonia64
  • fall62
  • cough56
  • illness55
  • influenza52
  • product dose omission41
  • vomiting41

Reports by year received

View as table
YearReports
20162
201748
2018223
2019155
2020193
2021255
2022246
2023387
2024340
2025325
2026240

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,745 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
poor venous accessSignal187160.3139.528,933
intentional dose omissionSignal27986.177.123,184
no adverse eventSignal55026.524.613,560
product dose omission issueSignal69720.719.413,200
device issueSignal18217.715.42,860
product dose omissionSignal415.54.0146
illnessSignal554.73.6155
covid-19Signal874.33.5221
influenzaSignal524.13.1118
pyrexiaSignal1102.82.3125
cough561.71.317
pneumonia641.71.419
fall621.61.314
malaise741.51.211
vomiting410.80.63

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.